NAD3® is the first nutraceutical to demonstrate an improvement in NAD+ status without utilizing a precursor. It's also the first NAD ingredient to show clinical benefits in humans.
CARLSBAD, Calif., May 5, 2022 /PRNewswire-PRWeb/ -- NAD3® is a multi-patents-pending nutraceutical containing a unique Wasabi Japonica extract, Theacrine and Copper(I)-Niacin complex. Preliminary pre-clinical and human studies suggest that NAD3® upregulates enzymes that boost the conversion of NAD+ precursors, such as niacin, niacinamide, nicotinamide riboside (NR) and/or NMN to NAD+, while also suppressing the activity of proteins that deplete and consume NAD+. Collectively, these data support the use of NAD3® in combination with any NAD+ precursor or "booster" (as an ideal companion) for amplifying net cellular NAD+ status.
Recently published in the prestigious journal Physiologia, human data from the ENHANCE Trial revealed that 12 weeks of oral supplementation with NAD3® decreased various independent cardiovascular risk factors (e.g., VLDL, TAGs, LDL-C and Total Cholesterol) by 16% to 19%. In the same study, beneficial changes in the NAD+/NADH ratio were noted despite the fact that NAD3® does NOT contain an appreciable dose of an NAD vitamin precursor. Taken together, the data provide a strong basis for including NAD3® as part of a comprehensive plan to optimize cardiometabolic health and longevity.
While it's still the "early days" for NAD3®, and much about how NAD+ influences human health and the biology of aging remains to be studied, JUVN3 Holdings continues to invest heavily in NAD3® research. JUVN3 is an ingredient incubator specializing in human longevity. Its NAD3® pipeline of mechanistic, pre-clinical science and human clinical research is well underway. They are committed to providing a solid body of clinical evidence that pushes the forefront of science, advances the field of longevity, and makes a positive impact on human healthspan for society.
While previous studies have demonstrated increases in NAD+ levels using supplement precursors (e.g. niacin, niacinamide, nicotinamide riboside (NR), NMN), NAD3® is the first nutraceutical to demonstrate an improvement in NAD+ status without utilizing a precursor. It's also the first NAD ingredient to show clinical benefits in humans.
NAD3® is distributed exclusively by Compound Solutions, Inc. (CSI) on behalf of JUVN3. Compound Solutions is the go-to company representing and distributing unique, patented nutraceutical ingredients that improve the health and performance of individuals. CSI supplies effective, science-based ingredients to wellness brands, sports nutrition, functional food and nutraceutical manufacturers. CSI is committed to building and maintaining long-term relationships with our global customers and suppliers.
*ENHANCE Trial: Effects of NAD3® on Hallmarks of Aging and Clinical Endpoints of Health in Middle Aged Adults: a subset analysis focused on blood cell NAD+ concentrations and lipid metabolism.
Media Contact
Kelsey Olanoff, Compound Solutions, Inc., 1 7607399881, [email protected]
SOURCE NAD3®
Share this article